Jeff Borgia, Ph.D. is the Director of the Rush Cancer Center Biorepository, where he oversees the collection and annotation of patient specimens in support of ongoing translational research projects ...

First in human (FIH) clinical trials of bispecific immunostimulatory antibodies commonly require a low starting dose based on a minimum anticipated biological effect level (MABEL) approach. To ...

In this free webinar, gain insight into method development and optimization of custom Laboratory Developed Test (LDT) assays, including critical steps identification and risk mitigation. Attendees ...

Applied Biosystems TaqPath assays are the first choice for probe-based qPCR assays that have been specifically designed for late-stage biotechnology and pharmaceutical applications. These products ...

HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today a series of enhancements for its QIAcuity series of digital PCR (dPCR) ...

SYGNIS AG, under the Innova Biosciences (Innova) brand name, a specialist provider of bioconjugation products and services, today announced it has established a partnership with Abingdon Health Ltd ...

SAN DIEGO--(BUSINESS WIRE)--Sapient, a leader in multi-omics discovery, has partnered with Alamar Biosciences, a pioneer in ultra-sensitive and highly multiplexed immunoassay technologies, to extend ...

QIAGEN N.V. QGEN recently launched the digital PCR (polymerase chain reaction) Custom Assay Design Tool for copy number variation (CNV) analysis for use on the QIAcuity digital PCR (dPCR) platform.

Avance Biosciences opened its new Potency and Cell-Based Assay Center of Excellence, a purpose-built facility designed to expand and centralize the company’s capabilities in potency and functional ...

Precision medicine is driven by advances in omics technologies that facilitate identification of mutations and the presence or absence of certain molecular targets, which, in turn, enables streamlined ...